2,002 Shares in Revvity, Inc. (NYSE:RVTY) Purchased by Balentine LLC

Balentine LLC bought a new position in shares of Revvity, Inc. (NYSE:RVTY) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 2,002 shares of the company’s stock, valued at approximately $219,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Byrne Asset Management LLC acquired a new position in shares of Revvity during the 4th quarter worth approximately $1,112,000. BNP Paribas Financial Markets bought a new position in shares of Revvity during the fourth quarter valued at $12,039,000. State of Michigan Retirement System bought a new position in shares of Revvity during the fourth quarter valued at $3,688,000. Gulf International Bank UK Ltd bought a new position in shares of Revvity during the fourth quarter valued at $1,136,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Revvity during the fourth quarter valued at $10,291,000. Institutional investors own 86.65% of the company’s stock.

Revvity Stock Down 0.7 %

RVTY opened at $111.89 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.23 and a quick ratio of 1.92. The company’s 50-day moving average is $104.57 and its 200 day moving average is $102.50. Revvity, Inc. has a fifty-two week low of $79.50 and a fifty-two week high of $131.96. The firm has a market capitalization of $13.81 billion, a P/E ratio of 92.47, a PEG ratio of 2.93 and a beta of 1.09.

Revvity (NYSE:RVTY) last announced its quarterly earnings data on Monday, April 29th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.94 by $0.04. The business had revenue of $649.90 million for the quarter, compared to analyst estimates of $646.83 million. Revvity had a net margin of 5.49% and a return on equity of 7.37%. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.01 earnings per share. Research analysts expect that Revvity, Inc. will post 4.66 earnings per share for the current fiscal year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.25%. The ex-dividend date is Friday, July 19th. Revvity’s dividend payout ratio is 23.14%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on RVTY shares. Robert W. Baird increased their price objective on shares of Revvity from $126.00 to $127.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 30th. KeyCorp increased their price objective on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. TD Cowen increased their price objective on shares of Revvity from $123.00 to $130.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Raymond James increased their price objective on shares of Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Finally, Barclays increased their price objective on shares of Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Revvity currently has a consensus rating of “Moderate Buy” and an average price target of $118.17.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.